When leukemia returns after chemotherapy, patients face difficult questions about next steps. Multiple treatment pathways exist, including reinduction chemotherapy, CAR-T cell therapy, allogeneic stem cell transplantation, and clinical trials. Eligibility depends on relapse timing, blast count, CD19 expression, and prior transplant status. Understanding these factors helps patients and families navigate treatment sequencing decisions. Key Takeaways Early relapse (<12 months)

When leukemia returns after chemotherapy, multiple evidence-based treatments remain available, including CAR-T cell therapy, stem cell transplant, targeted immunotherapy, and clinical trials. Treatment selection depends on relapse timing, patient fitness, leukemia subtype, and whether the disease returned within or after 12 months of achieving remission. Key Takeaways Multiple treatment options exist for relapsed leukemia, with cure still possible depending on timing and pati

TL;DR Chemotherapy resistance develops through acquired mechanisms including genetic mutations, efflux pumps, and clonal evolution that allow cancer cells to survive treatment Dr. Bharat Patodiya provides advanced molecular profiling to identify specific resistance patterns and guide personalized treatment strategies Alternative therapies including CAR-T cell therapy, TIL therapy, and gene therapy offer hope for patients with chemotherapy-resistant blood cancers Early consult